Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.66 |
| ▸ | RAB9A | P51151 | 5/20 | 0.62 |
| ▸ | NPC1 | O15118 | 4/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.62 |
| ▸ | HPGD | P15428 | 3/20 | 0.62 |
| ▸ | PKM | P14618 | 1/20 | 0.62 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.62 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.62 |
| ▸ | RELA | Q04206 | 1/20 | 0.62 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.60 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.60 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.60 |
| ▸ | LMNA | P02545 | 2/20 | 0.60 |
| ▸ | TSHR | P16473 | 1/20 | 0.60 |
| ▸ | CASP1 | P29466 | 1/20 | 0.60 |
| ▸ | TP53 | P04637 | 1/20 | 0.55 |
| ▸ | RECQL | P46063 | 2/20 | 0.54 |
| ▸ | THRB | P10828 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24751 | 0.89 | HSD17B1 (0.62) | ALDH1A1RAB9ANPC1SMN1; SMN2HPGD | |
| Bromide SCHEMBL28862925 | 0.87 | HSD17B1 (0.61) | ALDH1A1RAB9ANPC1SMN1; SMN2HPGD | |
| SCHEMBL2170056 | 0.86 | ALDH1A1 (0.64) | ALDH1A1RAB9ANPC1SMN1; SMN2HPGD | |
| SCHEMBL836745 | 0.86 | SMN1; SMN2 (0.65) | ALDH1A1RAB9ANPC1SMN1; SMN2HPGD | |
| SCHEMBL28727291 | 0.86 | SMN1; SMN2 (0.65) | ALDH1A1RAB9ANPC1SMN1; SMN2HPGD | |
| SCHEMBL14020195 | 0.84 | NPC1 (0.55) | ALDH1A1RAB9ANPC1SMN1; SMN2HPGD | |
| SCHEMBL14020155 | 0.84 | PDE10A (0.58) | ALDH1A1RAB9ANPC1SMN1; SMN2HPGD | |
| SCHEMBL1304947 | 0.84 | HSD17B1 (0.66) | ALDH1A1RAB9ANPC1SMN1; SMN2HPGD | |
| SCHEMBL13833772 | 0.84 | HSD17B1 (0.58) | ALDH1A1RAB9ANPC1SMN1; SMN2HPGD | |
| SCHEMBL569032 | 0.84 | ALDH1A1 (0.67) | ALDH1A1RAB9ANPC1SMN1; SMN2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 113 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250074938-A1 | CELL-PERMEANT INHIBITORS OF VIRAL CYSTEINE PROTEASES | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2025-03-06 | — | — | US | claimed |
| WO-2023114516-A2 | CELL-PERMEANT INHIBITORS OF VIRAL CYSTEINE PROTEASES | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2023-06-22 | — | — | WO | claimed |
| CN-107530302-A | salicylate inhibitors of ME L K and methods of use | 丹娜法伯癌症研究院 | 2018-01-02 | — | — | CN | claimed |
| CN-106459044-A | Tank-binding kinase inhibitor compounds | 吉利德科学公司 | 2017-02-22 | — | — | CN | claimed |
| CN-101863923-B | Novel inhibitors of chymase | JANSSEN PHARMACEUTICA NV | 2013-04-24 | — | — | CN | claimed |
| CN-101878031-A | The inhibitors of kinases that is used for the treatment of myeloproliferative disease and other proliferative diseases | DECIPHERA PHARMACEUTICALS LLC | 2010-11-03 | — | — | CN | claimed |
| CN-101863923-A | New inhibitors of chymase | JANSSEN PHARMACEUTICA NV | 2010-10-20 | — | — | CN | claimed |
| CN-101801383-A | Kinase inhibitors for the treatment of myeloproliferative and other proliferative diseases | DECIPHERA PHARMACEUTICALS LLC | 2010-08-11 | — | — | CN | claimed |
| CN-101553233-A | Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases | DECIPHERA PHARMACEUTICALS LLC (US) | 2009-10-07 | — | — | CN | claimed |
| CN-101553232-A | Kinase inhibitors useful for the treatment of proliferative diseases | DECIPHERA PHARMACEUTICALS LLC (US) | 2009-10-07 | — | — | CN | claimed |
| CN-1917882-A | Therapeutic combinations of atypical antipsychotics with corticotropin releasing factor antagonists | PFIZER (US) | 2007-02-21 | — | — | CN | claimed |
| CN-1882552-A | Derivatives of 1,3-diones having a herbicidal activity | ISAGRO RICERCA SRL (IT) | 2006-12-20 | — | — | CN | claimed |
| CN-1281688-C | Preparation of diketopyrrolo-pyrrole pigment | CLARIANT INT LTD (CH) | 2006-10-25 | — | — | CN | claimed |
| CN-1780626-A | Treatment of bipolar disorder and related symptoms | PFIZER (US) | 2006-05-31 | — | — | CN | claimed |
| CN-1546472-A | Pyridyl alkane acid amides as cytostatics and immunosupressives | ���ָ���ҩ�ɷ�����˾ | 2004-11-17 | — | — | CN | claimed |
| CN-1328091-A | Preparation of diketopyrrolo-pyrrole pigment | CLARIANT INT LTD (CH) | 2001-12-26 | — | — | CN | claimed |
| CN-1216923-A | Inclusion complexes of aryl-heterocyclic salts | PRIZER INC (US) | 1999-05-19 | — | — | CN | claimed |
| CN-1083061-A | The method for preparing arylpiperazinyl-heterogeneous ring compound | PFIZER (US) | 1994-03-02 | — | — | CN | claimed |
| CN-1015057-B | process for preparation of piperazinyl-heterocyclic compounds | PFIZER (US) | 1991-12-11 | — | — | CN | claimed |
| CN-88101642-A | Piperazinyl-heterogeneous ring compound | — | 1988-09-14 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250074938-A1 | CELL-PERMEANT INHIBITORS OF VIRAL CYSTEINE PROTEASES | ACE, TMPRSS2, ACE2 | ALDH1A1 2858/4885RAB9A 1929/4885NPC1 167/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.